A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke
Latest Information Update: 20 Jul 2021
At a glance
- Drugs ReN 001 (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms PISCES III
- Sponsors ReNeuron
- 08 Jul 2021 Status changed from active, no longer recruiting to discontinued, due to strategic decision to progress stroke disability programme through regional partnerships.
- 17 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Jun 2020 According to an ReNeuron media release, patient recruitment in this study with CTX in stroke disability, which has been on hold due to COVID-19 related restrictions, will remain suspended in the U.S. for the foreseeable future; clinical trial sites will be kept open and patients already treated will be followed up over time in line with the clinical trial protocol.